Cancer Tumor Profiling Market Overview
The Cancer Tumor Profiling Market was valued at USD 5.64 billion in 2024 and is expected to grow from USD 6.04 billion in 2025 to USD 12.0 billion by 2035, registering a CAGR of 7.1% during the 2026–2035 forecast period. Market expansion is being supported by the rising prevalence of cancer, advances in genomic technologies, increasing demand for personalized medicine, favorable government initiatives, and growing healthcare expenditure.
North America is expected to maintain its dominant position, with the regional market valued at USD 3.0 billion in 2024 and projected to reach USD 5.0 billion by 2035. The region benefits from advanced healthcare infrastructure, substantial research and development investments, and high adoption of precision oncology technologies. Asia-Pacific is also expected to witness strong growth as healthcare systems improve and investments in advanced cancer diagnostics increase.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=606316
Key Companies in the Cancer Tumor Profiling Market
Thermo Fisher Scientific
PathAI
Agilent Technologies
Foundation Medicine
QIAGEN
Invitae
Strata Oncology
Illumina
Roche
Myriad Genetics
Exact Sciences
Oncocyte
EMBLEM Health
Freenome
Caris Life Sciences
Guardant Health
NanoString Technologies
The Cancer Tumor Profiling Market is driven by increasing demand for targeted therapies and more precise cancer diagnosis. Next-generation sequencing and bioinformatics are improving the ability to identify genetic alterations and characterize tumor biology. Liquid biopsy is gaining traction because it provides a less invasive approach for profiling tumors and monitoring treatment responses. Artificial intelligence and machine learning are also enhancing the analysis of complex genomic data and supporting personalized treatment strategies.
The market is segmented by technology, application, cancer type, end use, and region. Technologies include Next-Generation Sequencing, Microarray Analysis, In Situ Hybridization, and Polymerase Chain Reaction. Applications include Biomarker Discovery, Therapeutic Target Identification, Drug Resistance Profiling, and Clinical Diagnostics. Cancer types include Breast Cancer, Lung Cancer, Colorectal Cancer, and Melanoma, while major end users include Hospitals, Research Laboratories, and Diagnostic Centers. Next-Generation Sequencing represented a leading technology segment, valued at approximately USD 3.0 billion in 2024 and projected to reach USD 5.0 billion by 2035.
Recent Developments and Market Trends:
Illumina announced a collaboration with Strata Oncology in March 2024 to integrate Strata’s tumor profiling capabilities with Illumina sequencing platforms.
Guardant Health announced a multi-year strategic contract with AstraZeneca in June 2024 to deploy blood-based genomic profiling in oncology trials.
Caris Life Sciences announced a major contract with Memorial Sloan Kettering Cancer Center in February 2024 to deploy Caris Molecular Intelligence across its oncology program.
Liquid biopsy adoption is increasing because of its minimally invasive nature and potential for treatment-response monitoring.
AI and machine learning are increasingly being integrated into genomic analysis to improve tumor characterization and personalized treatment planning.
Reasons to Buy the Report:
Understand the market size, growth rate, and forecast outlook of the global Cancer Tumor Profiling Market.
Analyze major technologies including next-generation sequencing, microarray analysis, in situ hybridization, and PCR.
Evaluate applications across biomarker discovery, therapeutic target identification, drug resistance profiling, and clinical diagnostics.
Assess opportunities across major cancer types including breast, lung, colorectal cancer, and melanoma.
Identify leading companies and understand the competitive landscape.
Examine regional growth opportunities across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
Understand the impact of personalized medicine, liquid biopsy, AI, and genomic technology advancements on future market growth.
Future Outlook:
The Cancer Tumor Profiling Market is expected to maintain strong growth through 2035 as precision oncology and personalized medicine become increasingly important in cancer management. Continued advances in next-generation sequencing, liquid biopsy, bioinformatics, and AI-driven genomic analysis are expected to improve tumor characterization and treatment selection. Expanding biomarker discovery, growing demand for early detection, and increased investment in cancer research should further broaden the adoption of tumor profiling technologies worldwide.
➤➤Explore Our Latest Related Reports:
